- Home
- KGS vs BLTE Comparison
KGS vs BLTE Comparison
Compare KGS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KGS | BLTE |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KGS | BLTE |
|---|---|---|
| Price | $54.84 | $188.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $46.80 | ★ $161.57 |
| AVG Volume (30 Days) | ★ 1.7M | 176.4K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | ★ 93.10 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $1,159,311,000.00 | N/A |
| Revenue This Year | $13.95 | N/A |
| Revenue Next Year | $8.78 | N/A |
| P/E Ratio | $86.48 | ★ N/A |
| Revenue Growth | ★ 36.33 | N/A |
| 52 Week Low | $29.25 | $49.00 |
| 52 Week High | $53.15 | $200.00 |
Technical Indicators
Market Signals| Indicator | KGS | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 80.03 | 64.31 |
| Support Level | $33.48 | $148.78 |
| Resistance Level | N/A | $200.00 |
| Average True Range (ATR) | 1.89 | 8.11 |
| MACD | 0.10 | 0.30 |
| Stochastic Oscillator | 95.00 | 80.49 |
Price Performance
Historical ComparisonAbout KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.